Ashish M Kamat

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers
    Ashish M Kamat
    Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
    Eur Urol 63:4-15. 2013
  2. ncbi Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL
    Goodwin Jinesh G
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Leukoc Biol 92:233-44. 2012
  3. ncbi Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial
    Ashish M Kamat
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 187:862-7. 2012
  4. ncbi The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    J Urol 175:881-5. 2006
  5. ncbi Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity
    Ashish M Kamat
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 108:1119-23. 2011
  6. ncbi Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:62-7. 2007
  7. ncbi Atorvastatin: a potential chemopreventive agent in bladder cancer
    Ashish M Kamat
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 66:1209-12. 2005
  8. ncbi Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 69:8958-66. 2009
  9. ncbi Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007
  10. ncbi Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
    Gordon A Brown
    Department of Urology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA
    BJU Int 98:1176-80. 2006

Research Grants

Detail Information

Publications92

  1. ncbi ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers
    Ashish M Kamat
    Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
    Eur Urol 63:4-15. 2013
    ..To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy...
  2. ncbi Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL
    Goodwin Jinesh G
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Leukoc Biol 92:233-44. 2012
    ..These findings explain the mechanism of action of BCG and identified Smac mimetics as potential combination therapeutic agents for bladder cancer...
  3. ncbi Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial
    Ashish M Kamat
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 187:862-7. 2012
    ..We initiated a prospective clinical trial to determine whether fluorescence in situ hybridization results during bacillus Calmette-Guérin immunotherapy can predict therapy failure...
  4. ncbi The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    J Urol 175:881-5. 2006
    ..Micropapillary bladder carcinoma is a rare variant of UC. Due to paucity of data regarding treatment outcomes, patients with nonmuscle invasive micropapillary UC often receive intravesical therapy in an attempt at bladder preservation...
  5. ncbi Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity
    Ashish M Kamat
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 108:1119-23. 2011
    ....
  6. ncbi Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:62-7. 2007
    ..Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience...
  7. ncbi Atorvastatin: a potential chemopreventive agent in bladder cancer
    Ashish M Kamat
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 66:1209-12. 2005
    ..As such, they are often prescribed HMG-CoA reductase inhibitors (statins), which have been suggested to affect tumor growth patterns...
  8. ncbi Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 69:8958-66. 2009
    ..Overall, our results suggest that curcumin potentiates the antitumor effect of BCG through the inhibition of NF-kappaB and induction of TRAIL receptors in bladder cancer cells...
  9. ncbi Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007
    ..The objective of the current study was to determine the clinical variables that predict this adverse outcome...
  10. ncbi Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
    Gordon A Brown
    Department of Urology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA
    BJU Int 98:1176-80. 2006
    ..To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period...
  11. ncbi A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:540-7. 2013
    ..Sequential chemotherapy also has not been well studied in the neoadjuvant setting. The authors explored sequential neoadjuvant ifosfamide-based chemotherapy in a patient cohort at high risk of noncurative cystectomy...
  12. ncbi Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer
    Philippe E Spiess
    Department of Urologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1483-90. 2006
    ..Advanced clinical stage and viable tumor in the surgical specimen predict worse RFS...
  13. ncbi Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:131-8. 2007
    ..We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients...
  14. ncbi Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy
    Robert S Svatek
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 76:1419-24. 2010
    ..POI is a common complication after radical cystectomy and can result in a prolonged hospital stay and delayed recovery...
  15. ncbi Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer
    Sara S Strom
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:631-9. 2006
    ..The current study sought to determine whether obesity was an independent predictor of biochemical failure (BF) and clinical recurrence (CF) among patients treated with external-beam radiotherapy (EBRT)...
  16. ncbi Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC
    Wassim Kassouf
    Department of Urology and the Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:121-6. 2008
    ..To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy...
  17. ncbi Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer
    Dan Leibovici
    Departments of Urology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 174:2186-90. 2005
    ..CONCLUSIONS: Radical CP provides effective and durable palliation in patients with locally advanced prostate cancer. This procedure can be performed with acceptable morbidity in a select group of patients...
  18. ncbi P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors
    Wassim Kassouf
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 52:769-74. 2007
    ..To improve our understanding of its significance in a contemporary series, we performed an outcomes analysis of this cohort of patients...
  19. ncbi Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy
    Gordon A Brown
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 70:252-6. 2007
    ..To evaluate whether the clinical grade predicts the final pathologic stage in upper urinary tract transitional cell carcinoma...
  20. ncbi Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era
    Wassim Kassouf
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1491-5. 2006
    ..This might be reflective of a paradigm shift that encompasses the adoption of multimodal therapy...
  21. ncbi Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection
    Robert S Svatek
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1310-7. 2009
    ....
  22. ncbi The role of radical cystectomy in patients with clinical T4b bladder cancer
    Peter C Black
    Department of Urology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 29:157-61. 2011
    ..We hypothesized that select patients might achieve durable benefit from multiagent chemotherapy and extirpative surgery...
  23. ncbi Malignant transformation of testicular teratoma: a chemoresistant phenotype
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 26:595-9. 2008
    ..To review our experience in the management of malignant transformation of teratoma (MTT)...
  24. ncbi Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience
    James G Evans
    Department of Urologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 176:1463-7. 2006
    ..Increasing amounts of preoperative chemotherapy and operative blood loss raise the likelihood of chylous ascites...
  25. ncbi Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy
    Charles J Rosser
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 67:769-73. 2006
    ..CONCLUSIONS: In the PSA era, men with prostate cancer who are 60 years old or younger and treated with surgery have an excellent biochemical disease-free outcome...
  26. ncbi Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?
    Philippe E Spiess
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Urology 67:466-71. 2006
    ..To compare treatment-related outcomes of immediate and staged urethrectomy in patients at high risk of urethral recurrence...
  27. ncbi Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:2592-7. 2009
    ..We now report results from the first phase II clinical trial developed exclusively for SCUC, to our knowledge...
  28. ncbi Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cell
    Ashish M Kamat
    Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Unit 143, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:1022-30. 2007
    ..Cigarette smoke-induced expression of the NF-kappaB-regulated gene products cyclooxygenase-2 and vascular endothelial growth factor, linked with proliferation and angiogenesis, respectively, was also down-regulated by curcumin...
  29. ncbi Management of urethral recurrence after orthotopic urinary diversion
    Jennifer M Taylor
    Department of Urology and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 106:56-61. 2010
    ..Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder...
  30. ncbi Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers
    Sheeja T Tharakan
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, United States
    Biochem Pharmacol 79:218-28. 2010
    ..Overall our results suggest that curcumin alone exhibits significant antitumor effects against human bladder cancer and it further potentiates the effects of gemictabine, possibly through the modulation of NF-kappaB signaling pathway...
  31. ncbi Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1224-33. 2009
    ..A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated with poor prognosis were identified...
  32. ncbi Vitamins C and K3 sensitize human urothelial tumors to gemcitabine
    Wassim Kassouf
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 176:1642-7. 2006
    ..3 mm3 daily) (p < 0.05). CONCLUSIONS: Vitamins C and K3 have significant antiproliferative and apoptotic effects when used in combination. This combination enhances the efficacy of gemcitabine against bladder cancer in vivo...
  33. ncbi Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure
    Ashish M Kamat
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 63:1132-7. 2004
    ..CONCLUSIONS: A PSA increase of 1.5 ng/mL or more above the 24-month nadir can be used to predict for ASTRO-defined failure after EBRT and may be used to identify patients at risk early-on...
  34. ncbi Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy
    Wassim Kassouf
    Department of Urology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 176:53-7; discussion 57. 2006
    ..Lymph node density remains a significant prognostic factor for recurrence-free survival even when adjuvant chemotherapy is used...
  35. ncbi Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer
    Ashish M Kamat
    Department of Urology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 170:1868-71. 2003
    ..This procedure can be performed with acceptable morbidity in a highly select group of patients...
  36. ncbi Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy
    M Zak Rajput
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas
    Urology 78:61-7. 2011
    ..To determine the effect of neoadjuvant chemotherapy on the surgical outcomes in patients undergoing laparoscopic radical nephroureterectomy (LNUX) for upper urinary tract urothelial carcinoma (UTUC)...
  37. ncbi Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort
    Robert S Svatek
    University of Texas Health Science Center San Antonio, San Antonio, TX, USA
    BJU Int 107:898-904. 2011
    ..To compare the clinical and pathologic stage among a large, multi-institutional series of patients undergoing radical and to determine the effect of stage discrepancy on outcomes...
  38. ncbi Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells
    Adam R Metwalli
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 10:885-92. 2010
    ..Finally, siRNA knockdown of XIAP was correlated with the sensitivity of cells to apoptosis induced by compound-A plus TRAIL by DNA fragmentation and western blotting...
  39. ncbi Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1503-10. 2006
    ..The objective of this study was to determine whether the presence of viable tumor in the surgical specimen could be predicted...
  40. ncbi Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:1330-4; discussion 1334. 2007
    ..We defined the growth rate and reviewed our experience in the surgical management of growing teratoma syndrome in patients with nonseminomatous germ cell tumors...
  41. ncbi Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer
    Charles J Rosser
    Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Med Assoc 96:939-44. 2004
    ..Continued diligence in screening and early detection may improve prostate cancer outcome for other minority populations...
  42. ncbi Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience
    Wassim Kassouf
    Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 175:2058-62. 2006
    ..Because late recurrence is not uncommon and is potentially life threatening, lifelong followup with cystoscopy is recommended...
  43. ncbi Review of the M.D. Anderson experience in the treatment of bladder sarcoma
    Philippe E Spiess
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Urol Oncol 25:38-45. 2007
    ..To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma...
  44. ncbi Upper tract urothelial carcinoma: impact of time to surgery
    Debasish Sundi
    Department of Urologic Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 30:266-72. 2012
    ..The purpose of this analysis is to examine the impact of such delay on survival outcomes...
  45. ncbi Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?
    Charles J Rosser
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 66:327-31. 2005
    ..To evaluate the effect of patient age on the occurrence of prostate-specific antigen (PSA) "bounce" after external beam radiotherapy (EBRT) for prostate cancer...
  46. ncbi Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection
    John W Davis
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 185:79-83. 2011
    ..Our primary objective was to determine the fraction of lymph nodes yielded by robot assisted pelvic lymph node dissection...
  47. ncbi Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy
    Rex Cheung
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:134-40. 2005
    ..By comparing the outcomes for patients who received RT alone and for those who received combined RT and hormonal therapy, we assessed the potential benefits of hormonal therapy...
  48. ncbi Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer
    Teruo Inamoto
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 27:585-91. 2009
    ..In this review, we summarize the data available regarding relevance of PPARgamma in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer...
  49. ncbi Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer
    Teruo Inamoto
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:340-6. 2010
    ..The authors have previously shown that Nurr1 is important in carcinogenesis. In the current study, they examined the clinicopathologic relevance of expression patterns of Nurr1 in bladder tumors...
  50. ncbi Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria
    Robert S Svatek
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 183:929-34. 2010
    ..0 to minimize interpretation bias and allow reliable comparisons with other populations...
  51. ncbi Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer
    Dan Leibovici
    Department of Urology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Prostate 62:101-4. 2005
    ..Although MRI is very specific, it cannot reliably rule out rectal involvement in the presence of a positive TRUS...
  52. ncbi High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation
    Surena F Matin
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Ultrasound Med 29:1277-84. 2010
    ..We analyzed endoluminal ultrasonography (ELUS) for evaluating renal pelvic and ureteral, or upper tract, urothelial carcinoma (UTUC)...
  53. ncbi Cardiac history and risk of post-cystectomy cardiac complications
    Mark B Fisher
    Department of Urology, MD Anderson Cancer Center, The University of Texas, Texas 77030, USA
    Urology 74:1085-9. 2009
    ..Patients undergoing cystectomy often have significant baseline cardiac disease. Despite preoperative medical optimization, postoperative cardiac complications remain a significant source of morbidity...
  54. ncbi Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder
    Jonathan L Wright
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Urol 178:2302-6; discussion 2307. 2007
    ..We investigated the survival of patients with the 2 tumor subtypes compared to survival in those with urothelial carcinoma...
  55. ncbi Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome
    Steven E Canfield
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 175:864-9. 2006
    ..Even in the absence of distant metastatic disease patients with positive nodes should be targeted for aggressive surgical resection, followed by clinical trials of adjuvant therapy to improve the outcome...
  56. ncbi International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
    Shahrokh F Shariat
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 105:1402-12. 2010
    ..To externally validate the prognostic value of lymphovascular invasion (LVI) in a large international cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB)...
  57. ncbi Contemporary intravesical treatment options for urothelial carcinoma of the bladder
    Stephen A Brassell
    Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 4:1027-36. 2006
    ....
  58. ncbi Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy
    Eugene K Lee
    Department of Urology Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 110:E590-5. 2012
    ..Using this information, we created prognostic tools incorporating lymph node density that can be used for risk stratification, patient counselling and clinical trial design...
  59. ncbi Novel therapeutics for patients with non-muscle-invasive bladder cancer
    Robert S Svatek
    The University of Texas MD Anderson Cancer Center, Division of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 9:807-13. 2009
    ....
  60. ncbi Focus on bladder cancer
    Colin P N Dinney
    Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX USA
    Cancer Cell 6:111-6. 2004
  61. ncbi Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy
    Ashish M Kamat
    Department of Urology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 170:1860-3. 2003
    ..9 ng/ml at presentation are at increased risk for recurrence after adjuvant RT...
  62. ncbi Contemporary management of locally invasive bladder cancer
    Rian J Dickstein
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 25:1396-405. 2011
    ..Consequently, further improvements in outcomes will rely on improved patient selection based on clinical and molecular assessments...
  63. ncbi Definition and management of patients with bladder cancer who fail BCG therapy
    Frances M Martin
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 9:815-20. 2009
    ..In this review, optimal risk stratification, appropriate definitions and management of BCG failures are discussed...
  64. ncbi Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer
    Meng Chen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 3:1235-45. 2010
    ..05), none remained significant after multiple-comparison adjustments. Germ-line genetic variations in the Shh pathway predicted clinical outcomes of TUR and BCG for NMIBC patients...
  65. ncbi Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors
    Ashish M Kamat
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 63:46-50. 2004
    ..If others confirm our finding that a high BMI confers a survival advantage to patients undergoing nephrectomy, BMI may prove to be an important prognostic factor in renal cell carcinoma...
  66. ncbi The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo
    Ashish M Kamat
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer Ther 3:279-90. 2004
    ..Together, our results demonstrate that bortezomib has significant antiproliferative activity in aggressive bladder cancer cells, which is best exploited within the context of combination chemotherapy...
  67. ncbi 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
    Teruo Inamoto
    Department of Urology, The University of Texas M D Anderson Cancer Center, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:3825-33. 2008
    ..These results identify Nurr1 as a potential target for bladder cancer therapy and also identify a novel agent for activating Nurr1...
  68. ncbi Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions
    Nancy P Caraway
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 111:323-9. 2007
    ..In this retrospective study, the reliability of quantitative digital cytometry (QDC) in conjunction with cytologic evaluation in detecting recurrent disease was determined in these patients...
  69. ncbi Bladder cancer stem cells
    Mai N Tran
    Departments of Urology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Curr Stem Cell Res Ther 5:387-95. 2010
    ..Herein, we identify and answer some of these questions to help readers better understand bladder cancer development and identify reasonable therapeutic strategy for targeting stem cells...
  70. ncbi Upper urinary tract tumors with nontransitional histology: a single-center experience
    J Erik Busby
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Urology 67:518-23. 2006
    ..Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy...
  71. ncbi Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy
    Charles J Rosser
    Department of Urology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 170:1856-9. 2003
    ..Improved screening and early detection may improve disease-free survival in Hispanic men with localized prostate cancer...
  72. ncbi Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists
    Wassim Kassouf
    Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Cancer Res 66:412-8. 2006
    ..Treatment of KU7 cells with DIM-C-pPhCF3 also elevated caveolin-1 expression by 25% to 30%, suggesting a role for this protein in mediating the antitumorigenic activity of DIM-C-pPhCF3 in bladder cancer...
  73. ncbi Considerations on the use of diagnostic markers in management of patients with bladder cancer
    Piyush K Agarwal
    Department of Urology, Unit 1373, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    World J Urol 26:39-44. 2008
    ..We will review diagnostic considerations in the use of these markers for the detection of recurrent bladder cancer and summarize the benefits and costs of the more promising bladder cancer markers...
  74. ncbi Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy
    Ashish M Kamat
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 174:1262-5. 2005
    ..In the absence of these criteria the incidence of ipsilateral positive margins is low. Thus, these criteria are valuable for predicting EPE and selecting patients for nerve sparing RP...
  75. ncbi High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk
    Meng Chen
    Department of Epidemiology and Urology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Carcinogenesis 28:2160-5. 2007
    ..The contributions of these polymorphisms may jointly affect bladder cancer risk through gene-gene and gene-smoking interactions...
  76. ncbi Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis
    Ashish M Kamat
    Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 23:130-1. 2005
    ..We present this case to alert physicians of the possibility of penile cancer in young Caucasian males as well as to demonstrate the significant morbidity and mortality that can ensue from a delay in diagnosis...
  77. ncbi Controversial issues and optimal management of stage T1G3 bladder cancer
    Adam R Metwalli
    The University of Texas MD Anderson Cancer Center, Department of Urology, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 6:1283-94. 2006
    ..Multifocal disease, concomitant carcinoma in situ and disease in the prostatic urethra and bladder neck also suggest aggressive disease and cystectomy should be considered in these patients...
  78. ncbi Chemoprevention of superficial bladder cancer
    Ashish M Kamat
    Department of Urology, University of Texas, MD Anderson Cancer Center, Houston 77030, USA
    Expert Rev Anticancer Ther 3:799-808. 2003
    ..A large body of evidence links diet and nutrition with bladder cancer. This review summarizes the efficacy of natural and synthetic agents that have purported chemopreventive activity...
  79. ncbi Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha
    Ashish M Kamat
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    J Urol 171:1886-7. 2004
  80. ncbi Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study
    Marylou Cardenas-Turanzas
    Department of Biostatistics, Health Services Research, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX, 77030 4009, USA
    Int Urol Nephrol 40:893-9. 2008
    ..We evaluated resource utilization and complication rates of patients undergoing radical cystectomy or exenteration using the Texas Hospital In-Patient Discharge Data Collection...
  81. ncbi Antitumor activity of common antibiotics against superficial bladder cancer
    Ashish M Kamat
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 63:457-60. 2004
    ..Preclinical data such as these must be considered in the design of clinical trials addressing recurrence after transurethral resection of bladder tumors...
  82. ncbi Current state of immunotherapy for bladder cancer
    Wassim Kassouf
    Department of Urology, Unit 446, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 4:1037-46. 2004
    ....
  83. ncbi Chemoprevention of bladder cancer
    Ashish M Kamat
    Department of Urology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Urol Clin North Am 29:157-68. 2002
    ..Encouraging patients to follow an essentially healthy food habit lifestyle will be a significant contribution in the fight against cancer...
  84. ncbi Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    Cancer 110:764-9. 2007
    ..Nonbilharzial squamous cell carcinoma (SCC) of the bladder is a rare entity in the Western hemisphere. To further understanding of its natural history, a contemporary experience with management and outcome of this disease was reviewed...
  85. ncbi Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy
    Charles J Rosser
    Division of Urology, University of Florida, Jacksonville, Florida 32209, USA
    Cancer 107:54-9. 2006
    ..The study was conducted to assess the results of radical prostatectomy (RP) performed by fellowship-trained surgeons in the first year of independent practice...
  86. ncbi Statins and the effect of BCG on bladder cancer
    Ashish M Kamat
    N Engl J Med 356:1276; author reply 1276-7. 2007
  87. ncbi Treatment of muscle-invasive bladder cancer: progress and new challenges
    Judi C Herring
    Division of Urology, Department of Surgery, University of Florida, 555 West Eighth Street, Pavilion, 2 South, Jacksonville, FL 32209, USA
    Expert Rev Anticancer Ther 4:1047-56. 2004
    ..In this review, data are presented with emphasis on the practical application of current knowledge to the management of patients with muscle-invasive bladder cancer...
  88. ncbi Treatment of bladder cancer in cardiac transplant patients
    Nadeem N Dhanani
    Department of Urology, University of Texas M. D. Anderson Cancer Center, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int Urol Nephrol 38:477-9. 2006
    ..This illustrates that cardiac transplant patients with superficial tumors may be managed with conservative therapies, but close vigilance is necessary to identify the opportune time for extirpative surgery...
  89. ncbi Intravesical BCG for bladder cancer: how much is enough?
    Ashish M Kamat
    Cancer 113:674-6. 2008
  90. ncbi Lymph node density: surrogate marker for quality of resection in bladder cancer?
    Ashish M Kamat
    Expert Rev Anticancer Ther 7:777-9. 2007
  91. ncbi Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Canada
    J Urol 180:164-7; discussion 167. 2008
    ..We determined the value of preoperative transurethral prostatic urethral biopsy in predicting final distal urethral margin status at radical cystectomy...
  92. ncbi Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis
    Andrew Shapiro
    Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 23:352-3. 2005
    ..This patient was thought to have peritoneal carcinomatosis. One must be cognizant of the possibility when evaluating patients with similar findings and images after bacillus Calmette-Guérin therapy...

Research Grants1

  1. Chemoprevention of murine urinary bladder carcinogenesis
    Ashish Kamat; Fiscal Year: 2005
    ..abstract_text> ..